SEC Filing Analysis: SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Executive Summary

• Trading Significance: High
• Key Takeaway: The President and CEO, Jack A. Khattar, executed a significant sale of common stock totaling approximately $3.03 million. This transaction was part of an option exercise and subsequent sale conducted under a pre-established Rule 10b5-1 trading plan.
• Market Impact: While a large sale by a CEO can be a bearish signal, the pre-planned nature of the transaction (10b5-1 plan) often neutralizes the immediate negative sentiment, as it indicates the sale was not based on recent adverse non-public information.

Company Information

Field	Value
Company	SUPERNUS PHARMACEUTICALS, INC.
Ticker Symbol	SUPN
CIK	0001356576
Industry	Pharmaceutical Preparations [2834]

Insider Information

Field	Value
Name	Khattar Jack A.
CIK	0001539937
Title/Position	President, CEO
Relationship	Director, Officer

Transaction Details

This filing reports a series of related transactions: an option exercise followed by sales of the acquired stock.

Summary of Sales:

Field	Value
Form Type	4
Transaction Date	2025-10-09
Transaction Code	S (Sale)
Security Type	Common Stock
Shares Involved	59,900 (total from two sales)
Avg Price Per Share	$50.57 (weighted average)
Total Value	$3,029,349.39
Shares Owned After	1,206,578 (Directly)
Ownership Type	Direct

Breakdown of Transactions:

1. Option Exercise (Code M): Acquired 81,250 shares of Common Stock by exercising employee stock options at a price of $25.30 per share.
2. Sale 1 (Code S): Sold 58,371 shares at a weighted average price of $50.55.
3. Sale 2 (Code S): Sold 1,529 shares at a weighted average price of $51.46.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral to Slightly Bearish
• Reasoning: A $3M sale by a CEO is substantial. However, the sale was conducted under a 10b5-1 plan adopted in November 2024, nearly a year prior. This significantly reduces the implication that the sale is timed to take advantage of a perceived stock price peak. The market may see this as a planned liquidity event for the executive rather than a loss of confidence.

Volume & Sentiment

• Expected Volume Impact: A short-term spike in trading volume around the transaction date is likely as the market absorbs the large block of shares.
• Sentiment Indicator: Initially Bearish due to the size of the sale, but likely to shift to Neutral as informed investors recognize the 10b5-1 plan context.

Investment Insights

Positive Market Indicators

• The insider still holds a very large position of over 1.2 million shares directly and over 1 million shares indirectly, indicating continued significant alignment with shareholder interests.
• Exercising options implies a belief that the market price is well above the exercise price, which is a positive sign.

Risk Factors

• The sale represents a significant cash-out for the CEO, which could be interpreted by some as profit-taking near a potential high.
• The optics of a top executive selling a large amount of stock are never entirely positive, regardless of the context.

Key Takeaways

1. Planned Liquidity: This is a classic example of an executive using a pre-scheduled plan to diversify their holdings and realize compensation from vested options.
2. Significant Remaining Stake: The CEO's remaining direct and indirect holdings are substantial, ensuring their financial interests remain closely tied to the company's success.
3. Context is Crucial: The presence of a 10b5-1 plan (disclosed in Footnote 1) is the most important piece of context for this transaction, differentiating it from a spontaneous open-market sale.

Contextual Analysis

Timing Significance

The transactions were executed on October 9, 2025. The key timing element is not the transaction date itself, but the date the 10b5-1 plan was adopted (November 14, 2024), which shows this was a long-term plan.

Transaction Context

The filing clearly outlines an 'exercise-and-sell' event. The insider exercised options that were granted years ago and were deeply in-the-money, then sold a portion of the acquired shares to cover the exercise cost and realize a profit. The sales were made at weighted average prices, as detailed in the footnotes.

Company Context

An investor should review Supernus Pharmaceuticals' recent performance, upcoming clinical trial data, earnings reports, and overall market sentiment for the pharmaceutical sector to place this insider transaction in a broader context.

Risk Assessment

Risk Level: Medium

Risk Factors

• Perception Risk: The market may have a knee-jerk negative reaction to the headline value of the sale before digesting the 10b5-1 context.
• Signal Risk: Could signal the executive's belief that the stock's near-term upside is limited, prompting them to lock in gains.

Market Considerations

• Sector Trends: The performance of the broader pharmaceutical and biotech sectors will influence how this news is received.
• Company Pipeline: The perceived strength of Supernus's drug pipeline and recent corporate developments are critical for long-term valuation.

---

IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.

Analysis generated on 2025-10-10 | Data source: SEC EDGAR